摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-dipropyl-8-bromo-3,7-dihydropurine-2,6-dione | 127946-27-4

中文名称
——
中文别名
——
英文名称
1,3-dipropyl-8-bromo-3,7-dihydropurine-2,6-dione
英文别名
1,3-dipropyl-8-bromoxanthine;8-bromo-1,3-dipropylxanthine;8-bromo-1,3-dipropyl-7H-purine-2,6-dione
1,3-dipropyl-8-bromo-3,7-dihydropurine-2,6-dione化学式
CAS
127946-27-4
化学式
C11H15BrN4O2
mdl
——
分子量
315.17
InChiKey
ZFLKZWJOIPYVKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    69.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,3-dipropyl-8-bromo-3,7-dihydropurine-2,6-dione氯化亚砜 作用下, 以 甲醇 为溶剂, 反应 48.25h, 生成 8-[Bis-(2-chloro-ethyl)-amino]-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
    参考文献:
    名称:
    Substituted 1,3-Dipropylxanthines as Irreversible Antagonists of A1 Adenosine Receptors
    摘要:
    This report describes the synthesis of 29 xanthines containing a chemoreactive chloroaryl beta-chloroethylamino, alpha,beta-unsaturated carbonyl bromoacetyl, 3-(fluorosulfonyl)benzoyl, or 4-(fluorosulfonyl)benzoyl group as part of an exocyclic 1-, 3-, or 8-substituent. The xanthines inhibited the binding of [H-3]-8-cyclopentyl-1,3-dipropylxanthine ([H-3]CPX) to the A(1) adenosine receptor (A(1)AR) of DDT1 MF2 cells at IC(50)s in the low-nanomolar to low-micromolar range. Seven of the 29 analogues irreversibly inhibited the binding of [H-3]CPX without changing the K-D of that ligand; five were 1,3-dipropylxantines having the following reactive groups as 8-substituents: (bromoacetamido)methyl (24), (bromoacetamido)ethyl (25), (bromoacetamido)propyl (26), [4-(fluorosulfonyl)benzamido]methyl (33) or 3-[[4-(fluorosulfonyl)benzoyl]oxy]cyclopentyl (42). Both 8-cyclopentyl-3-[3-[[4-(fluorosulfonyl)benzoyl]oxy]propyl]-1-propylxanthine (53) and 8-cyclopentyl-3-bis[3-[[4-(fluorosulfonyl)benzoyl]oxy]propyl]xanthine (55) inhibited [H-3]CPX binding irreversibly. Five of the ligands, including 26, 33 (IC50 = 49 mu M), and 53 (IC50 = 9 mu M), antagonized the binding of [H-3]NECA to the A(2a)AR of PC12 cells, but unlike binding to the A(1)AR, binding to the A(2a)AR was completely reversible. The potency of 33 (IC50 = 2 mu M, 72% loss of CPX binding at 1 mu M) and 53 (IC50 - 0.01 mu M, 74% loss of CPX binding at 0.05 mu M) and their seletivity for the A(1)AR suggest that those two ligands may be useful in studies of the structure and function of that receptor.
    DOI:
    10.1021/jm00043a010
  • 作为产物:
    描述:
    3,9-二氢-1,3-二丙基-1H-嘌呤-2,6-二酮sodium chlorate氢溴酸溶剂黄146 作用下, 以 为溶剂, 反应 2.0h, 以78%的产率得到1,3-dipropyl-8-bromo-3,7-dihydropurine-2,6-dione
    参考文献:
    名称:
    N9-苄基取代的1,3-二甲基-和1,3-二丙基-嘧啶[2,1-f]嘌呤二酮:在腺苷A1和A2A受体上的合成与构效关系。
    摘要:
    描述了N-苄基嘧啶[2,1-f]嘌呤二酮的合成及其理化性质。这些衍生物是通过将7-氯丙基o-8-溴-1,3-二甲基-或1,3-二丙基黄嘌呤衍生物与相应的(未)取代的苄胺环合而合成的。也可以在微波辐射条件下获得二丙基衍生物。评价获得的化合物(1-20)对腺苷A1和A2A受体的亲和力,另外研究所选化合物对A3受体亚型的亲和力。放射性配体对A1和A2A腺苷受体的结合测定结果表明,大多数1,3-二甲基-9-苄基嘧啶嘌呤二酮在微摩尔或亚微摩尔浓度下均表现出对A2A受体的选择性亲和力(例如,具有邻甲氧基取代基的衍生物9在大鼠A2A受体上的Ki值为0.699 microM,选择性超过36倍。与先前描述的芳基嘧啶并[2,1-f]嘌呤二酮二丙基衍生物(化合物15-20)相反,对两种受体的亲和力均增加,但A1亲和力增加的幅度更大,结果取消了A2A的选择性。最佳的腺苷A1受体配体是间氯苄基衍生物18(Ki = 0
    DOI:
    10.1016/j.bmc.2007.04.018
点击查看最新优质反应信息

文献信息

  • Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors
    作者:T. Katsushima、L. Nieves、J. N. Wells
    DOI:10.1021/jm00169a012
    日期:1990.7
    least 1000-fold more potent as an antagonist of A1 than of A2 adenosine receptors. While most substitutions on the 8-cycloalkyl moiety caused decreased potency to inhibit both A1 and A2 adenosine receptors, 8-[trans-4-(acetamidomethyl)cyclohexyl]-1,3-dipropylxanthine was nearly equipotent as an antagonist of the two receptors and appeared to be the most potent antagonist of A2 adenosine receptors reported
    8-取代的黄嘌呤目前代表最有效的腺苷-受体拮抗剂。制备了一系列8-取代的1,3-二丙基黄嘌呤,并确定了它们分别作为人血小板和大鼠脂肪细胞的A1和A2腺苷受体拮抗剂的效力。没有研究药物能像A1腺苷受体拮抗剂那样与8-环戊基-1,3-二丙基黄嘌呤一样有效,但是8-(2-甲基环丙基)-1,3-二丙基黄嘌呤比A1腺苷受体的效力至少强1000倍。 A1比A2的腺苷受体高。虽然8-环烷基部分上的大多数取代都导致抑制A1和A2腺苷受体,8- [反式-4-(乙酰氨基甲基)环己基] -1的效力降低,
  • N9-Benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: Synthesis and structure–activity relationships at adenosine A1 and A2A receptors
    作者:Anna Drabczyńska、Christa E. Müller、Janina Karolak-Wojciechowska、Britta Schumacher、Anke Schiedel、Olga Yuzlenko、Katarzyna Kieć-Kononowicz
    DOI:10.1016/j.bmc.2007.04.018
    日期:2007.7
    affinity to adenosine A1 and A2A receptors, selected compounds were additionally investigated for affinity to the A3 receptor subtype. The results of the radioligand binding assays to A1 and A2A adenosine receptors showed that most of the 1,3-dimethyl-9-benzylpyrimidopurinediones exhibited selective affinity to A2A receptors at micromolar or submicromolar concentrations (for example, derivative 9 with o-methoxy
    描述了N-苄基嘧啶[2,1-f]嘌呤二酮的合成及其理化性质。这些衍生物是通过将7-氯丙基o-8-溴-1,3-二甲基-或1,3-二丙基黄嘌呤衍生物与相应的(未)取代的苄胺环合而合成的。也可以在微波辐射条件下获得二丙基衍生物。评价获得的化合物(1-20)对腺苷A1和A2A受体的亲和力,另外研究所选化合物对A3受体亚型的亲和力。放射性配体对A1和A2A腺苷受体的结合测定结果表明,大多数1,3-二甲基-9-苄基嘧啶嘌呤二酮在微摩尔或亚微摩尔浓度下均表现出对A2A受体的选择性亲和力(例如,具有邻甲氧基取代基的衍生物9在大鼠A2A受体上的Ki值为0.699 microM,选择性超过36倍。与先前描述的芳基嘧啶并[2,1-f]嘌呤二酮二丙基衍生物(化合物15-20)相反,对两种受体的亲和力均增加,但A1亲和力增加的幅度更大,结果取消了A2A的选择性。最佳的腺苷A1受体配体是间氯苄基衍生物18(Ki = 0
  • Structure–activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A3 adenosine receptor antagonists
    作者:Pier Giovanni Baraldi、Delia Preti、Mojgan Aghazadeh Tabrizi、Romeo Romagnoli、Giulia Saponaro、Stefania Baraldi、Maurizio Botta、Cesare Bernardini、Andrea Tafi、Tiziano Tuccinardi
    DOI:10.1016/j.bmc.2008.10.049
    日期:2008.12.15
    We recently described the synthesis of 1-benzyl-3-propyl-1H,8H-imidazo[2,1-f]purine-2,4-diones, new potent and selective A(3) adenosine receptor antagonists containing a xanthine core. The present work can be considered an extension of our SAR studies on related structures in which the effect of different kind of substitutions at the 1-, 3- and 8-positions has been evaluated in order to improve both the potency and the hydrophilicity of the originally synthesised molecules. The A(3) binding disposition of these compounds was also investigated through docking and 3D-QSAR studies. (C) 2008 Elsevier Ltd. All rights reserved.
  • KATSUSHIMA, T.;NIEVES, L.;WELLS, J. N., J. MED. CHEM., 33,(1990) N, C. 1906-1910
    作者:KATSUSHIMA, T.、NIEVES, L.、WELLS, J. N.
    DOI:——
    日期:——
  • Scammells Peter J., Baker Stephen P., Belardinelli Luiz, Olsson Ray A., J. Med. Chem, 37 (1994) N 17, S 2704-2712
    作者:Scammells Peter J., Baker Stephen P., Belardinelli Luiz, Olsson Ray A.
    DOI:——
    日期:——
查看更多